ST
Developing novel therapeutics to restore gut lymphatic function.
About
Seaport Therapeutics is a biotechnology company focused on developing novel therapeutics that restore gut lymphatic function. Their lead candidate, GlyphCele™, is the first oral therapeutic designed for this purpose and has received significant funding from ARPA-H to advance its development.
Tags
Total Employees
64
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
69Traction
58Team
70Visibility
7Profile
0Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Seaport Therapeutics do?
Seaport Therapeutics is a biotechnology company focused on developing novel therapeutics that restore gut lymphatic function. Their lead candidate, GlyphCele™, is the first oral therapeutic designed for this purpose and has received significant funding from ARPA-H to advance its development.
How much funding has Seaport Therapeutics raised?
Seaport Therapeutics has raised a total of $340M in funding. The most recent round on record is Unknown.
Where is Seaport Therapeutics headquartered?
Seaport Therapeutics is headquartered in Cambridge, Massachusetts, USA.
When was Seaport Therapeutics founded?
Seaport Therapeutics was founded in 2021.
What industry does Seaport Therapeutics operate in?
Seaport Therapeutics operates in Biotechnology, Pharmaceuticals, HealthTech.
How many employees does Seaport Therapeutics have?
Seaport Therapeutics has approximately 64 people on record.
Similar Startups